RxDoctor Payments Data

Alison Tucker, MD

Family Medicine · Louisville, KYNPI 1568604353

Payments from drug & device makers

$2,053in general payments, 2019–2025

Across 61 payments — averaging $33.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$517
  • Exact Sciences$317
  • Amgen$293
  • Phathom Pharmaceuticals, Inc.$232
  • GSK$187
  • Biohaven Pharmaceutical Holding Company Ltd.$114
  • plus $393 from 14 others

What the payments were for

  • Food & beverage$2,053100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,053 in reported general payments places this provider in the 70th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$131,100
Medicare patients
250
Services billed
1,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$48,421
EliquisApixaban64$47,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$44,267
RybelsusSemaglutide36$43,217
OzempicSemaglutide22$35,999
JanuviaSitagliptin Phosphate34$33,154
VascepaIcosapent Ethyl38$31,088
InvokanaCanagliflozin23$29,048
Repatha SureclickEvolocumab27$27,638
XareltoRivaroxaban17$25,554
Janumet XrSitagliptin Phos/Metformin Hcl18$23,936
TrintellixVortioxetine Hydrobromide19$14,374
Soliqua 100-33Insulin Glargine/Lixisenatide15$12,129
FarxigaDapagliflozin Propanediol14$11,448
Icosapent Ethyl17$10,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvokana, Xarelto$38$54,60340 claims
Lilly USA, LLCMounjaro$62$48,42142 claims
PfizerEliquis$517$47,51864 claims
GSKTrelegy Ellipta$187$44,26760 claims
AstraZenecaFarxiga$11$11,44814 claims
AbbVieSynthroid$27$4,35577 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →